Evofem Biosciences amends merger agreement with Aditxt, exchanges $1.573M notes for Series G-1 Preferred Stock

Evofem Biosciences, Inc.

• Sixth Amendment to A&R Merger Agreement updated definitions to include Series G-1 Preferred, set dissenting share cap at 5,932,818 common shares and 202 preferred shares.
• Exchanged $1.573M aggregate principal of senior secured convertible notes for 1,573 Series G-1 Preferred shares (stated value $1,000/share, conversion price $0.0154).
• Series G-1 Preferred carries voting rights (as-converted), monthly dividends in stock or PIK, and trigger-event conversion at alternative prices with 25% premium.
• Amendment requires waivers from all Series E-1 Preferred holders on price adjustment and other provisions, and updated exchange agreement for convertible noteholders.
• Merger with Aditxt remains pending; proxy statement to be filed for shareholder vote.